GLP-1 Medications: A Defining Moment for Pharma

GLP-1 medications are transforming the landscape of metabolic health, with consumer demand surging. And yet, a gap between interest and adoption remains, pointing to an opportunity for pharma. 

A recent Healthgrades survey of consumers exploring weight-loss options found that while 23% of consumers have used or are currently using a weight-loss medication, an overwhelming 82% are eager to try GLP-1s—a clear signal of unmet demand.¹

Pharma brands can act now to define the next era of metabolic health. By taking a strategic, patient-first approach, they can reinforce trust, improve accessibility, and drive physician engagement—three critical areas for unlocking the full potential of GLP-1 therapies.

Pharma Opportunity #1: Reinforcing Consumer Trust

GLP-1s already have strong consumer trust, and pharma must continue to reinforce this confidence.

Consumers believe in GLP-1s’ effectiveness, with 84% expecting greater weight-loss success than with previous methods.¹ Three-quarters anticipate appetite suppression and reduced cravings, while 65% believe GLP-1s will boost metabolism and prolong fullness.¹

To strengthen this trust, pharma should align messaging with the distinct motivations of different patient groups. Among those interested in GLP-1s, 59% have been diagnosed as overweight or obese—a demographic often over 45, with lower incomes.¹ Half have been advised by a doctor to lose weight, particularly those facing health concerns like sleep apnea.¹

Weight loss is not just about aesthetics; for many, it is a medical necessity. Nearly half (47%) of consumers seek weight loss to prevent chronic conditions, while 41% already have conditions that could improve with GLP-1 therapy.¹ Additionally, 10% are pursuing weight loss to qualify for elective surgeries such as knee or hip replacements.¹

Pharma must continue positioning GLP-1s as science-backed solutions for sustainable health improvements, while ensuring messaging speaks to the real-life motivations of diverse patient groups.

Pharma Opportunity #2: Addressing Consumer Barriers

High interest does not always translate into access. Pharma should address cost, insurance coverage, and supply challenges head-on—and brands that lead in transparency and affordability will earn stronger long-term loyalty.

Cost is a major barrier. Nearly half (48%) of consumers say GLP-1s are too expensive, with prices ranging from $500 to $1,300 per month.¹ Only 22% say they can afford the lowest-cost option, and just 12% report that their insurance covers these medications.¹ 

Compounded semaglutide versions have emerged as a response to shortages and high costs, but they present safety and efficacy risks. These non-FDA-approved alternatives may contain inconsistent ingredients, leading to potential overdoses or ineffective treatment. Physician sentiment is divided: 38% prescribe them due to shortages, while 34% refuse due to safety concerns.²

Pharma brands can differentiate themselves by improving access and ensuring patient safety:

• Partner with insurers to expand coverage and reduce out-of-pocket costs.
• Explore the direct-to-patient options that drugmakers are increasingly offering.
• Introduce tiered pricing models or subscription-based payment plans.
• Educate consumers on the risks of compounded alternatives and reinforce the benefits of FDA-approved medications.

Pharma Opportunity #3: Multi-Channel Consumer and Physician Education

Despite widespread interest, many consumers still lack knowledge about GLP-1 therapy. Pharma must invest in multi-channel education strategies, including physician engagement, patient-friendly digital content, and direct-to-consumer campaigns.

More than one-third (36%) of consumers have heard of GLP-1s but don’t know much about them.¹ Four in 10 mistakenly believe they will only need to take the medication for a year, unaware that long-term use is often necessary to maintain weight loss.¹

This knowledge gap underscores the need for clear, accessible education on:

• The science behind GLP-1s and their metabolic benefits.
• The importance of adherence for sustained weight management.
• Cost and coverage options to improve access.

Physicians also need better support. While 47% say they proactively discuss GLP-1s with eligible patients,² only a third of consumers say their doctor has mentioned these treatments.¹ Cost and coverage remain the biggest hurdles—89% of physicians cite financial concerns as a barrier to prescribing.²

Pharma brands can empower doctors by:

• Offering patient assistance programs to alleviate cost concerns.
• Providing clear, compelling clinical data on safety and efficacy.
• Educating HCPs on the risks of compounded alternatives to ensure responsible prescribing.

How Pharma Can Lead the Future of GLP-1s

The demand for GLP-1s is reshaping chronic disease care, and pharma brands must think beyond sales to establish long-term leadership in metabolic health.

To drive responsible adoption and maximize patient impact, brands should:

• Invest in ongoing patient education to close knowledge gaps and set realistic expectations.
• Champion affordability initiatives to make these life-changing therapies more accessible.
• Strengthen physician partnerships to reinforce trust and expand treatment conversations.

The future of GLP-1 therapy is being written now. The brands that take action, lead the conversation, and put patients first will be the ones that define the next generation of chronic disease treatment.

¹ Consumer Condition Research on GLP-1 Medication, Suzy panel survey, May 2024; N=978 consumers
² Healthgrades Physician Survey, N=152 physicians